Clinical Features and Treatment Outcomes of Bloodstream Infections Caused by Extended-Spectrum β-Lactamase-Producing Escherichia coli Sequence Type 131.

Despite the remarkable emergence of extended-spectrum β-lactamase (ESBL)-producing Escherichia coli sequence type 131 (ST131), the clinical features and outcomes of infections caused by ST131 remain poorly described. From 2011 to 2012, we collected ESBL-producing E. coli isolates from patients with bloodstream infections in 13 hospitals in Korea and compared clinical characteristics and outcomes between ST131 and non-ST131 clones. Of the 110 ESBL-producing isolates, the most common ST was ST131 (30.9%). Multivariate analysis showed that recent operation was the only variable associated with the ST131 clone; other comorbid conditions and clinical features were similar between ST131 and non-ST131 clones. CTX-M-14 and CTX-M-15 were the predominant types of ESBLs, and CTX-M-15 was significantly associated with ST131. The rate of nonsusceptibility to ciprofloxacin was higher in ST131 than in non-ST131 clones (94.1% vs. 75.0%). No significant differences in 30-day mortality rates were found between ST131 and no...

[1]  S. Brisse,et al.  Different Factors Associated with CTX-M-Producing ST131 and Non-ST131 Escherichia coli Clinical Isolates , 2013, PloS one.

[2]  K. Ko,et al.  Clinical and Molecular Epidemiology of Community-Onset Bacteremia Caused by Extended-Spectrum β-Lactamase-Producing Escherichia coli over a 6-Year Period , 2013, Journal of Korean medical science.

[3]  C. Lohse,et al.  Escherichia coli Sequence Type 131 Is a Dominant, Antimicrobial-Resistant Clonal Group Associated with Healthcare and Elderly Hosts , 2013, Infection Control & Hospital Epidemiology.

[4]  J. K. Lee,et al.  Clinical impact of inappropriate initial antimicrobial therapy on outcome in bacteremic biliary tract infections , 2013, Scandinavian journal of infectious diseases.

[5]  M. Kaku,et al.  Molecular characteristics of extended-spectrum β-lactamase-producing Escherichia coli in Japan: emergence of CTX-M-15-producing E. coli ST131. , 2012, Diagnostic microbiology and infectious disease.

[6]  S. Park,et al.  Molecular epidemiology of extended-spectrum β-lactamase-producing Escherichia coli in the community and hospital in Korea: emergence of ST131 producing CTX-M-15 , 2012, BMC Infectious Diseases.

[7]  G. Kahlmeter,et al.  Antimicrobial susceptibility to parenteral and oral agents in a largely polyclonal collection of CTX‐M‐14 and CTX‐M‐15‐producing Escherichia coli and Klebsiella pneumoniae , 2011, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[8]  Hsing-Chun Chung,et al.  Bacteremia Caused by Extended-Spectrum-β-Lactamase-Producing Escherichia coli Sequence Type ST131 and Non-ST131 Clones: Comparison of Demographic Data, Clinical Features, and Mortality , 2011, Antimicrobial Agents and Chemotherapy.

[9]  D. Paterson,et al.  Escherichia coli O25b-ST131: a pandemic, multiresistant, community-associated strain. , 2011, The Journal of antimicrobial chemotherapy.

[10]  G. Peirano,et al.  Molecular epidemiology of Escherichia coli producing CTX-M beta-lactamases: the worldwide emergence of clone ST131 O25:H4. , 2010, International journal of antimicrobial agents.

[11]  D. Paterson,et al.  Emergence of High Levels of Extended-Spectrum-β-Lactamase-Producing Gram-Negative Bacilli in the Asia-Pacific Region: Data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) Program, 2007 , 2009, Antimicrobial Agents and Chemotherapy.

[12]  K. Ko,et al.  Prevalence and characterization of extended-spectrum beta-lactamase-producing Enterobacteriaceae isolated in Korean hospitals. , 2008, Diagnostic microbiology and infectious disease.

[13]  E. Denamur,et al.  The CTX-M-15-producing Escherichia coli diffusing clone belongs to a highly virulent B2 phylogenetic subgroup. , 2008, The Journal of antimicrobial chemotherapy.

[14]  F. Baquero,et al.  Dissemination of Clonally Related Escherichia coli Strains Expressing Extended-Spectrum β-Lactamase CTX-M-15 , 2008, Emerging infectious diseases.

[15]  J. Cheesbrough,et al.  Major Uropathogenic Escherichia coli Strain Isolated in the Northwest of England Identified by Multilocus Sequence Typing , 2008, Journal of Clinical Microbiology.

[16]  J. Blanco,et al.  Intercontinental emergence of Escherichia coli clone O25:H4-ST131 producing CTX-M-15. , 2007, The Journal of antimicrobial chemotherapy.

[17]  G. Rossolini,et al.  The spread of CTX-M-type extended-spectrum β-lactamases , 2008 .

[18]  Y. Carmeli,et al.  Mortality and delay in effective therapy associated with extended-spectrum beta-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis. , 2007, The Journal of antimicrobial chemotherapy.

[19]  Jungmin Kim,et al.  CTX-M and SHV-12 beta-lactamases are the most common extended-spectrum enzymes in clinical isolates of Escherichia coli and Klebsiella pneumoniae collected from 3 university hospitals within Korea. , 2005, FEMS microbiology letters.

[20]  Daniel J Sexton,et al.  Health CareAssociated Bloodstream Infections in Adults: A Reason To Change the Accepted Definition of Community-Acquired Infections , 2002, Annals of Internal Medicine.

[21]  K. Thomson,et al.  Detection of extended-spectrum beta-lactamases in members of the family Enterobacteriaceae: comparison of the double-disk and three-dimensional tests , 1992, Antimicrobial Agents and Chemotherapy.